Yes, gene therapies are not only being developed but have recently reached a historic milestone in the United Kingdom. For the first time, a targeted genetic therapy has been approved for use in the UK to treat a specific inherited form of Motor Neurone Disease (MND). This marks a fundamental shift in the field, moving from general symptom management to precision medicine that addresses the underlying genetic cause of the disease. While these therapies currently apply to a small percentage of the MND population, they provide a proven template for future treatments targeting other genetic and sporadic forms of the condition.
The most common approach in current gene therapy research involves a technology called Antisense Oligonucleotides. These are synthetic molecules designed to find and bind to specific genetic instructions, effectively switching off the production of toxic proteins before they can damage motor neurones. This article explores the recent approval of the first gene therapy in the UK, the ongoing research into other genetic mutations, and how these advancements are integrated into clinical care.
What We Will Discuss In This Article
- The landmark approval of Tofersen for SOD1-MND in the UK
- Current gene therapy research for the C9orf72 and FUS mutations
- How Antisense Oligonucleotide technology works at a cellular level
- The role of genetic testing and counselling in accessing these therapies
- Future directions including gene editing and broad neuroprotective strategies
- Emergency guidance for acute health or treatment related complications
The First Approved Gene Therapy: Tofersen
In July 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for Tofersen, making it the first treatment in nearly 30 years to target a genetic cause of MND in the UK.
- Target Population: Tofersen is specifically for adults with MND caused by a mutation in the SOD1 gene, which accounts for approximately 2 percent of all MND cases.
- Mechanism: It is an Antisense Oligonucleotide therapy that reduces the levels of the toxic SOD1 protein produced by the faulty gene.
- Delivery: The treatment is administered via a lumbar puncture at regular intervals by a healthcare professional.
- Clinical Impact: Evidence from clinical trials has shown that Tofersen can significantly lower biomarkers of nerve damage and slow the decline of physical function in some patients.
Ongoing Research: C9orf72 and FUS Mutations
While Tofersen is currently the only licensed gene therapy, research is actively pursuing treatments for other common hereditary forms of MND.
Targeting C9orf72
The C9orf72 mutation is the most frequent genetic cause of MND, found in about 1 in 12 cases. Research focuses on molecular tools that can block the production of toxic protein clumps associated with this mutation. While some early trial results have been mixed, refined versions of these therapies are continually being tested in clinical environments across the UK.
FUS and Other Rare Mutations
Targeted trials are also underway for the FUS gene mutation, which often affects younger individuals. By reducing the accumulation of mutant FUS protein in motor neurones, these therapies aim to preserve nerve function and prolong life. Researchers are also exploring gene silencing for other less common mutations.
The Path to Clinical Access in the UK
Having a drug licensed by the MHRA is the first step. For a gene therapy to be widely available on the NHS, it must be appraised by the National Institute for Health and Care Excellence (NICE).
- Current Status of Tofersen: As of early 2026, Tofersen is being appraised by NICE via the Highly Specialised Technologies route. This specific pathway is used for treatments targeting very rare conditions, allowing for a fair assessment of its value.
- NICE Timeline: Formal assessments are expected to continue through 2026, with full evidence submissions due mid year.
- Early Access Programmes: While the appraisal is in progress, many patients in the UK have been able to access Tofersen free of charge through a manufacturer sponsored Early Access Programme at specialist MND centres.
The Role of Genetic Testing
The rise of gene therapy makes genetic testing more important than ever. In the UK, guidelines ensure that individuals diagnosed with MND can access genetic screening and specialist counselling. Knowing your genetic status is the only way to determine eligibility for current licensed gene therapies or recruitment into specific clinical trials.
Emergency Guidance
While gene therapies represent a breakthrough, they involve invasive delivery methods and complex biological interactions. Seek emergency care immediately if you experience:
- Signs of an acute infection at the site of a lumbar puncture such as severe redness, swelling, or pus
- A sudden, severe headache that is worse when standing or accompanied by a stiff neck
- Rapid onset of confusion, high fever, or a significant change in mental alertness
- New or worsening difficulty breathing or swallowing
- Signs of an allergic reaction shortly after a treatment session such as hives or swelling of the face
In these situations, call 999 or contact your specialist neurology team immediately.
To Summarise
Gene therapy for Motor Neurone Disease has transitioned from a research concept to a clinical reality in the United Kingdom. With the approval of Tofersen for SOD1-MND and ongoing trials for other significant mutations like C9orf72 and FUS, the era of precision medicine for MND has arrived. These treatments aim to address the root genetic cause of the disease, offering hope for stabilisation and slowed progression. While the process of making these therapies universally available on the NHS continues, the foundation has been laid for a future where many more forms of MND can be treated with targeted, life altering genetic interventions.
Can these gene therapies work for sporadic MND?
Currently, therapies like Tofersen are designed for specific genetic mutations. However, the technology is also being researched for sporadic MND by targeting universal pathways, such as the regulation of proteins like UNC13A which are affected in 97 percent of all cases.
How do I get tested for MND genes?
You should discuss this with your neurologist or GP. In the UK, you can be referred to a Clinical Genetics service where you will receive counselling to help you decide if testing is right for you and your family.
Are there risks to having a lumbar puncture for these treatments?
Common side effects include a temporary headache, back pain, or tiredness. Rare but serious risks like inflammation of the spinal cord are closely monitored by the specialist medical team.
Is CRISPR gene editing being used for MND?
While CRISPR is being used in laboratory research to study MND, it is not yet a standard clinical treatment. Current gene therapies focus on interfering with the genetic instructions rather than permanently altering the DNA.
Authority Snapshot
This article was reviewed by Dr. Rebecca Fernandez, a UK trained physician with an MBBS and extensive experience in internal medicine, general surgery, and psychiatry. Dr. Fernandez has managed critically ill patients and stabilized acute trauma cases, giving her a deep understanding of the safety protocols and clinical monitoring required for advanced medical interventions like gene therapy. Her background in evidence based psychological therapies ensures a holistic perspective, recognizing the significant mental health support and clarity required for patients and families navigating the complexities of genetic testing and new medical breakthroughs.
